Multiple Myeloma · Teclistamab BCMA × CD3 bispecific (with step-up dosing) — continuous SC weekly

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	aggressive
Linked regimen	`REG-TECLISTAMAB`

ID	`IND-MM-4L-TECLISTAMAB`
Type	Indication
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	`DIS-MM`
Sources	`SRC-ESMO-MM-2023` `SRC-MAJESTEC-1-MOREAU-2022` `SRC-NCCN-MM-2025`

Notes

STUB — pending Clinical Co-Lead sign-off. Aggressive-track 4L+ option for triple-class refractory MM. Talquetamab (GPRC5D × CD3), elranatamab (BCMA × CD3), cilta-cel + ide-cel CAR-T are alternative modalities — separate future Indications. International referral pathway is dominant access barrier.

Used By

Algorithms

ALGO-MM-2L - ALGO-MM-2L
ALGO-MM-3L - ALGO-MM-3L

Indication

IND-MM-4L-CILTACEL-CART - IND-MM-4L-CILTACEL-CART
IND-MM-RR-3L-TECLISTAMAB - IND-MM-RR-3L-TECLISTAMAB